X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (154) 154
middle aged (126) 126
adult (119) 119
female (117) 117
male (114) 114
hematology (110) 110
index medicus (89) 89
transplantation (88) 88
aged (86) 86
treatment outcome (68) 68
transplantation, homologous (59) 59
oncology (55) 55
stem cells (55) 55
hematopoietic stem cell transplantation (49) 49
disease-free survival (48) 48
hematology, oncology and palliative medicine (47) 47
article (44) 44
immunology (44) 44
bone-marrow-transplantation (41) 41
antineoplastic combined chemotherapy protocols - therapeutic use (40) 40
adolescent (37) 37
chemotherapy (35) 35
cancer (34) 34
recurrence (34) 34
retrospective studies (34) 34
survival rate (34) 34
transplantation conditioning - methods (34) 34
prognosis (32) 32
survival analysis (32) 32
leukemia (31) 31
combined modality therapy (29) 29
rituximab (29) 29
graft vs host disease - prevention & control (28) 28
remission induction (28) 28
therapy (28) 28
young adult (28) 28
hematopoietic stem cell transplantation - methods (26) 26
transplantation conditioning (26) 26
hematopoietic stem cells (25) 25
vidarabine - analogs & derivatives (25) 25
care and treatment (24) 24
follow-up studies (24) 24
hematopoietic stem cell transplantation - adverse effects (24) 24
survival (23) 23
transplantation, autologous (23) 23
non-hodgkins-lymphoma (22) 22
stem-cell transplantation (22) 22
acute myeloid-leukemia (21) 21
bone-marrow transplantation (21) 21
stem cell transplantation (21) 21
lymphomas (20) 20
cyclophosphamide - administration & dosage (19) 19
leukemia, lymphocytic, chronic, b-cell - therapy (19) 19
cyclophosphamide (18) 18
hemic and lymphatic diseases (17) 17
minimal residual disease (17) 17
risk factors (17) 17
fludarabine (16) 16
graft vs host disease - etiology (16) 16
analysis (15) 15
chronic lymphocytic-leukemia (15) 15
lymphoma (15) 15
lymphoma, non-hodgkin - therapy (15) 15
mortality (15) 15
versus-host-disease (15) 15
abridged index medicus (14) 14
antineoplastic agents - therapeutic use (14) 14
antineoplastic combined chemotherapy protocols - administration & dosage (14) 14
graft vs tumor effect (14) 14
high-dose chemotherapy (14) 14
vidarabine - administration & dosage (14) 14
antibodies, monoclonal - therapeutic use (13) 13
busulfan (13) 13
child (13) 13
leukemia, myeloid, acute - therapy (13) 13
melphalan (13) 13
relapse (13) 13
acute myelogenous leukemia (12) 12
aged, 80 and over (12) 12
antibodies, monoclonal, murine-derived (12) 12
blood (12) 12
bone marrow transplantation (12) 12
disease (12) 12
graft vs host disease - mortality (12) 12
melphalan - administration & dosage (12) 12
myelodysplastic syndrome (12) 12
total-body irradiation (12) 12
vidarabine - therapeutic use (12) 12
allogeneic stem cell transplantation (11) 11
allografts (11) 11
bone marrow transplantation - adverse effects (11) 11
chronic myelogenous leukemia (11) 11
cytogenetics (11) 11
hematologic neoplasms - therapy (11) 11
immunosuppressive agents - therapeutic use (11) 11
myelodysplastic syndromes - therapy (11) 11
patient outcomes (11) 11
prospective studies (11) 11
research (11) 11
surgical procedures, operative (11) 11
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 02/2017, Volume 123, Issue 3, pp. 459 - 467
BACKGROUND The introduction of novel prognostic factors such as minimal residual disease (MRD) and genomic profiling has led to the reevaluation of the role of... 
hypodiploidy | minimal residual disease | cytogenetics | prognosis | acute lymphoblastic leukemia (ALL) | complex | ACUTE LYMPHOCYTIC-LEUKEMIA | REGIMEN | PHASE-2 | CHILDREN | THERAPY | ONCOLOGY | PREDICTORS | OUTCOMES | Neoplasm, Residual - pathology | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative - diagnosis | Prognosis | Humans | Middle Aged | Male | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative - drug therapy | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Cytodiagnosis | Aged, 80 and over | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative - genetics | Vincristine - administration & dosage | Adult | Female | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative - pathology | Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology | Doxorubicin - administration & dosage | Treatment Outcome | Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis | Remission Induction | Cytarabine - administration & dosage | Neoplasm, Residual - genetics | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Disease-Free Survival | Adolescent | Aged | Usage | Research | Doxorubicin | Vincristine | Risk factors | Chemotherapy | Cyclophosphamide | Cytogenetics | Dosage and administration | Acute lymphocytic leukemia | Drug therapy | Cancer | Dexamethasone | Profiling | Acute lymphatic leukemia | Hypodiploidy | Leukemia | Abnormalities | Minimal residual disease | Lymphatic leukemia | Multivariate analysis | Patients | Survival | Philadelphia chromosome | Medical prognosis | Adults | Triploidy | Pretreatment
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2010, Volume 28, Issue 14, pp. 2365 - 2372
Journal Article
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, ISSN 1520-4391, 2006, pp. 390 - 397
Journal Article
Cancer, ISSN 0008-543X, 01/2017, Volume 123, Issue 2, pp. 294 - 302
BACKGROUND Minimal residual disease (MRD) assessment predicts survival for patients with newly diagnosed acute lymphoblastic leukemia (ALL). Its significance... 
relapsed | refractory | inotuzumab | blinatumomab | minimal residual disease | acute lymphoblastic leukemia | ADULT PATIENTS | PROGNOSIS | INOTUZUMAB OZOGAMICIN | ACUTE LYMPHOCYTIC-LEUKEMIA | INDUCTION | TRANSPLANTATION | ONCOLOGY | FLOW-CYTOMETRY | MRD | CLINICAL-SIGNIFICANCE | Neoplasm, Residual - pathology | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology | Humans | Middle Aged | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Antineoplastic Agents - therapeutic use | Neoplasm Recurrence, Local - mortality | Neoplasm Recurrence, Local - pathology | Young Adult | Disease-Free Survival | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Stem Cell Transplantation - methods | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Adolescent | Aged, 80 and over | Adult | Aged | B-Lymphocytes - pathology | Hematopoietic Stem Cell Transplantation - methods | Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology | Salvage Therapy - methods | Flow cytometry | Cell survival | Acute lymphatic leukemia | Identification methods | Leukemia | Minimal residual disease | Stem cell transplantation | Transplantation | Lymphatic leukemia | Patients | Survival | Doxorubicin | Vincristine | Cytometry | Cyclophosphamide | Salvage | Lymphocytes B | Stem cells | Remission | Adults | Cancer | Acute lymphoblastic leukemia
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 03/2018, Volume 24, Issue 5, pp. 1011 - 1018
Purpose: Prevention or treatment of relapsed lymphoid malignancies after hematopoietic stem cell transplantation (HSCT) requires novel strategies. We... 
MULTIPLE-MYELOMA | SURVIVAL | METASTATIC MELANOMA | CTLA-4 BLOCKADE | RELAPSE | ONCOLOGY | RITUXIMAB | ANTIBODY | FOLLICULAR LYMPHOMA | THALIDOMIDE ANALOG | ANTITUMOR IMMUNITY | Graft vs Host Disease - epidemiology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Graft vs Host Disease - immunology | CD4-Positive T-Lymphocytes - immunology | Dose-Response Relationship, Drug | Neoplasm Recurrence, Local - immunology | Neoplasm Recurrence, Local - pathology | Lymphoma - therapy | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | Lymphoma - pathology | Ipilimumab - administration & dosage | Transplantation, Homologous - adverse effects | Drug Administration Schedule | Neoplasm Recurrence, Local - therapy | Lymphoma - immunology | Treatment Outcome | Ipilimumab - adverse effects | Transplantation, Autologous - methods | Lenalidomide - administration & dosage | Pilot Projects | Graft vs Host Disease - chemically induced | Lenalidomide - adverse effects | Transplantation, Autologous - adverse effects | Aged | Hematopoietic Stem Cell Transplantation - methods | CD4-Positive T-Lymphocytes - drug effects | Transplantation, Homologous - methods | Graft-versus-host reaction | Intravenous administration | Transplants & implants | Toxicity | Stem cell transplantation | Cytotoxicity | Transplantation | Lymphocytes T | Dermatitis | Hematopoietic stem cells | Safety engineering | Foxp3 protein | Remission | Autografts | Immune response | Risk groups | Hypothyroidism | Patients | CD4 antigen | Hemopoiesis | Experimental design | Cell number | ICOS protein | Stem cells | Antitumor activity | Cancer
Journal Article
Journal Article
Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, ISSN 1078-0432, 05/2018, Volume 24, Issue 10, pp. 2304 - 2311
Purpose: We evaluated the effect on long-term survival of adding rituximab (R) to BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning with or... 
Transplants & implants | Clinical trials | Stem cell transplantation | Transplantation | Cytarabine | Melphalan | Remission | Conditioning | Medical research | Autografts | Cell survival | Etoposide | Rituximab | Patients | Survival | Lymphoma | Yttrium isotopes | Chemotherapy | Lymphocytes B | Experimental design | Stem cells | Lymphomas | Yttrium | Cancer | B-cell lymphoma
Journal Article
Blood, ISSN 0006-4971, 09/2008, Volume 112, Issue 6, pp. 2586 - 2587
Journal Article
British Journal of Haematology, ISSN 0007-1048, 09/2014, Volume 166, Issue 6, pp. 891 - 901
Journal Article
Cancer, ISSN 0008-543X, 2/2017, Volume 123, Issue 3, pp. 459 - 467
Condensed Abstract: In adult patient with ALL, low hypodiploidy/near triploidy and complex karyotype are associated with worse survival independent of MRD... 
hypodiploidy | minimal residual disease | Acute lymphoblastic leukemia | cytogenetics | prognosis | complex
Journal Article
Cancer, ISSN 0008-543X, 12/2016, Volume 122, Issue 24, pp. 3812 - 3820
In patients with ALL receiving induction, increased blasts on Day 14 BM assessment is associated with lower CR rates and worse survival. The impact of Day 14... 
blasts | minimal residual disease | Acute lymphoblastic leukemia | day 14 | prognosis
Journal Article
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2014, Volume 20, Issue 12, pp. 1975 - 1981
Journal Article